BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. (BCTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bctx · pe ratio · data through Jul 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for BriaCell Therapeutics Corp. (BCTX) measures how much investors pay for each dollar of the company's trailing earnings. BCTX's current PE ratio of N/A is calculated by dividing its stock price of $3.09 by its TTM earnings per share of -$10.57.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-07-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
BriaCell Therapeutics Corp.You BCTX | $6M | N/A | — | -$10.57 |
 Allarity Therapeutics, Inc. ALLR | $25M | N/A | — | -$0.78 |
 Aspire Biopharma Holdings, Inc. ASBP | $1M | N/A | — | -$16.38 |
 Curis, Inc. CRIS | $6M | N/A | — | -$0.06 |
 Citius Pharmaceuticals, Inc. CTXR | $7M | N/A | — | -$3.38 |
 Entero Therapeutics, Inc. ENTO | $14M | N/A | — | -$4.05 |
 Hoth Therapeutics, Inc. HOTH | $18M | N/A | — | -$0.90 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-07-31Latest FY2025 | — | $-19.37 | — | |
2024-07-31 FY2024 | — | $-4.37 | — | |
2023-07-31 FY2023 | — | $-26.04 | — | |
2022-07-31 FY2022 | — | $-33.32 | — | |
2021-07-31 FY2021 | — | $-57.31 | — | |
2020-07-31 FY2020 | — | $-103.86 | — | |
2019-07-31 FY2019 | — | $-150.55 | — | |
2018-07-31 FY2018 | — | $-189.61 | — | |
2017-07-31 FY2017 | — | $-142.07 | — | |
2016-07-31 FY2016 | — | $-116.05 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for BriaCell Therapeutics Corp. (BCTX) measures how much investors pay for each dollar of the company's trailing earnings. BCTX's current PE ratio of N/A is calculated by dividing its stock price of $3.09 by its TTM earnings per share of -$10.57.
Frequently asked questions
BCTX pe ratio · 6 questionsBCTX's current PE ratio is N/A as of 2026-06-08, based on a stock price of $3.09 and TTM EPS of -$10.57. Data sourced from Financial Modeling Prep via BCTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · BriaCell Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08